Voyageur Pharmaceuticals Ltd. VYYRF
0.09 USD 0.00 (-4.30%)
Regular-session close
0.085 Day range 0.089
0.0033 52-week range 1.03
- YTD
- -31.59%
- 1 year
- -31.33%
News
newsfilecorp.com Voyageur Pharmaceuticals Announces Completion of Shares for Debt Settlement Calgary, Alberta--(Newsfile Corp. - October 2, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium…
newsfilecorp.com Voyageur Pharmaceuticals Announces Proposed Issuance of Shares for Debt Calgary, Alberta--(Newsfile Corp. - September 24, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), Canadian developer of pharmaceutical-grade barium…
thenewswire.com Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment CALGARY, Alberta – TheNewswire - September 9, 2026 – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) (“ Voyageur ” or the “ Company ”), a Canadian developer of pharmaceutical-grade barium…
thenewswire.com Voyageur Pharmaceuticals Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing CALGARY, Alberta – August 10, 2026 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) (“Voyageur” or the “Company”), a Canadian developer of pharmaceutical-grade barium and…
newsfilecorp.com Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker Calgary, Alberta--(Newsfile Corp. - July 17, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and…
thenewswire.com Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility CALGARY, Alberta – TheNewswire - June 23, 2026 – Voyageur Pharmaceuticals Ltd . ( TSX.V: VM ) (OTC Pink: VYYRF) (“ Voyageur ” or the “ Company ”), a Canadian developer of pharmaceutical-grade barium…
thenewswire.com Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway CALGARY, Alberta – June 18, 2026 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (“Voyageur” or the “Company”), a Canadian developer of pharmaceutical-grade barium and…
thenewswire.com Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project Calgary, Alberta – TheNewswire - June 10, 2026 – Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the " Company " or " Voyageur ") announces the submission of a Multi-Year Area-Based (" MYAB ") Notice of…
thenewswire.com Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption Calgary, Alberta, Canada – June 5, 2026 – TheNewswire – Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the " Company " or " Voyageur "), a Canadian developer of pharmaceutical-grade barium and iodine for…
thenewswire.com Voyageur Announces Update To Non-Brokered Life Offering Calgary, Alberta, Canada – May 1, 2026 - TheNewswire – Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the " Company " or " Voyageur "), a Canadian developer of pharmaceutical-grade barium and iodine for…
thenewswire.com Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt Purity Exceeding Pharmaceutical Grade, 98.8% BaSO4
thenewswire.com Voyageur Pharmaceuticals Announces Collaboration with Bayer Calgary, Alberta, Canada – TheNewswire – February 23, 2026 - Voyageur Pharmaceuticals Ltd. ( TSXV:VM ) ( OTC Pink:VYYRF) (" Voyageur " or the " Company ") a Canadian developer of pharmaceutical-grade…
thenewswire.com Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology Calgary, Alberta, Canada – TheNewswire - January 12, 2026 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium…
thenewswire.com Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion Calgary, AB – November 7, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) (the “Company” or “Voyageur”), a Canadian developer of pharmaceutical-grade barium and iodine for…
thenewswire.com Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with PHALANX Calgary, Alberta, Canada – October 29, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a Canadian public company developing…
thenewswire.com Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion Calgary, AB – October 23, 2025 - TheNewswire – Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF), (the “Company” or “Voyageur”) a Canadian developer of pharmaceutical-grade barium and iodine for…
thenewswire.com Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform Calgary, Canada – TheNewswire – August 25, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) ("Voyageur" or the "Corporation") is pleased to announce the launch of its U.S.-based iodine…
thenewswire.com Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics Calgary, Alberta, Canada – August 21, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company"), a radiology contrast media company focused on…
thenewswire.com Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million Calgary, Alberta, Canada – TheNewswire - August 19, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“ Voyageur ” or the “ Company ”), a company with a strategic focus on vertically…
proactiveinvestors.com Voyageur Pharmaceuticals partners with VAST on Frances Creek permitting work Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has brought on VAST Resource Solutions Inc. to advance permitting at its Frances Creek barite project, part of the company's push to develop a…
